Skip to main content

Table 3 Guideline-adherent treated breast cancer inpatients per therapy sequence and distribution of guideline divergences

From: The adherence paradox: guideline deviations contribute to the increased 5-year survival of breast cancer patients

N (%) Institutional-invasive samples Regional invasive samples
  1996–97 2003–04 p-valuea 1996–97 2003–04 p-valuea
Surgical strategy incl. irradiation 99 (28.7) 210 (52.8) <0.001 72 (30.3) 138 (51.9) <0.001
Lymph node dissection 279 (80.9) 323 (81.2) n.s. 188 (79.0) 209 (78.6) n.s.
Planned chemotherapy 257 (74.5) 371 (93.2) <0.001 183 (76.9) 245 (92.1) <0.001
Planned hormontherapy 242 (70.1) 336 (84.4) <0.001 162 (68.1) 223 (83.8) <0.001
Adherence overall 46 (13.3) 140 (35.2) <0.001 36 (15.1) 89 (33.5) <0.001
Divergence overall 299 (86.7) 258 (64.8) 202 (84.9) 177 (66.5)
  1. Legend: All tests are adjusted for multiple testing, (n.s.) non-significant test results